...
机译:对VRC01相2B疗效试验进行累积整体预防疗效
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
NIH Vaccine Res Ctr Bldg 10 Bethesda MD 20892 USA;
Duke Univ Dept Med Durham NC USA;
Harvard Med Sch Beth Israel Deaconess Med Ctr Dept Med Boston MA USA;
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
NIH Vaccine Res Ctr Bldg 10 Bethesda MD 20892 USA;
Fred Hutchinson Canc Res Ctr Vaccine &
Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;
Antibody Mediated Prevention Trial; broadly neutralizing antibody; non-human primate challenge study; population pharmacokinetics; statistical modeling of HIV prevention efficacy; VRC01;
机译:对VRC01相2B疗效试验进行累积整体预防疗效
机译:2B阶段和3阶段预防试验中的某些设计问题,用于测试产品或概念的有效性。
机译:TiNIDrakizumab在中度至重度慢性牙菌牛皮癣患者中患者人口统计和疾病特征的疗效和疾病特征的疗效
机译:反麻布疫苗接种试验中疫苗疗效估计的回归模型的比较 - 大型前瞻性疫苗接种试验
机译:第3期临床试验的回顾性分析,评价患有慢性肾病的贫血药物B的疗效
机译:为VRC01 2b期2b功效试验建模累积总体预防功效
机译:对VRC01相2B疗效试验进行累积整体预防疗效